Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression

Journal of Neural Transmission

Volumn 118, Issue 12, 2011, Pages 1691-1702

  Jenner, P ^a   McCreary, A C ^b   Scheller, D K A ^c  

^a Guy's Campus   (United Kingdom)

^b CHARLES RIVER LABORATORIES   (United States)

^c UCB PHARMA   (Belgium)

Author keywords

CDD; CDS; Duodopa; Dyskinesia; L dopa; Rotigotine

Indexed keywords

APOMORPHINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; POSTSYNAPTIC RECEPTOR; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

BASAL GANGLION; BRAIN DEPTH STIMULATION; COMPETITIVE INHIBITION; CONTINUOUS DOPAMINERGIC STIMULATION; CONTINUOUS DRUG DELIVERY; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DYSKINESIA; HUMAN; MONOTHERAPY; NERVE STIMULATION; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTIPARKINSON AGENTS; DRUG DELIVERY SYSTEMS; DYSKINESIA, DRUG-INDUCED; HUMANS; PARKINSON DISEASE;

EID: 84855189322     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0703-9     Document Type: Review

References (93)

1. A Antonini IU Isaias M Canesi, et al. 2007 Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome Mov Disord 22 1145 1149 17661426 10.1002/mds.21500 (Pubitemid 47067225)
2. A Antonini F Mancini M Canesi, et al. 2008 Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease Neurodegener Disord 5 244 246 10.1159/000113714 1:CAS:528:DC%2BD1cXjs1WhtbY%3D (Pubitemid 351347862)
3. Apokyn (apomorphine hydrochloride injection) prescribing information (2004)Vernalis Pharmaceuticals Incorporated, Morristown
4. NS Bamford S Robinson RD Palmiter, et al. 2004 Dopamine modulates release from corticostriatal terminals J Neurosci 24 9541 9552 15509741 10.1523/JNEUROSCI.2891-04.2004 1:CAS:528:DC%2BD2cXpvFOrurY%3D (Pubitemid 39441508)
5. F Baronti MM Mouradian Davis TL, et al. 1992 Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease Ann Neurol 32 776 781 1471868 10.1002/ana.410320611 1:STN:280:DyaK3s7htFOjsA%3D%3D
6. Belluzzi JD, Domino EF, May JM et al (1994) N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 9:147-154 (Pubitemid 24092329)
7. F Bibbiani LC Costantini R Patel, et al. 2005 Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates Exp Neurol 192 73 78 15698620 10.1016/j.expneurol.2004.11.013 1:CAS:528: DC%2BD2MXhtVKgsr8%3D (Pubitemid 40208539)
8. PJ Blanchet F Calon JC Martel, et al. 1995 Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys J Pharmacol Exp Ther 272 854 859 7853204 1:CAS:528:DyaK2MXjs1OhtL0%3D
9. B Boroojerdi HM Wolff M Braun DK Scheller 2010 Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome Drugs Today (Barc) 46 7 483 505 10.1358/dot.2010.46.7.1463530 1:STN:280: DC%2BC3cjisVKjsg%3D%3D
10. M Braun W Cawello K Poole, et al. 2005 Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease Eur J Neurol 12 S2 96
11. W Cawello M Braun H Boekens 2009 Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery Drug Metab Dispos 37 2055 2060 19608695 10.1124/dmd.109.027383 1:CAS:528:DC%2BD1MXht1amsLnK
12. TN Chase 1998 The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease Drugs 55 S1 1 9 9483164 10.2165/00003495-199855001-00001 (Pubitemid 28051032)
13. A Colzi K Turner AJ Lees 1998 Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease J Neurol Neurosurg Psychiatry 64 573 576 9598668 10.1136/jnnp.64.5.573 1:STN:280:DyaK1c3lvVKitw%3D%3D (Pubitemid 28204140)
14. R de la Fuente-Fernandez V Sossi, et al. 2004 Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 127 2747 2754 15329355 10.1093/brain/awh290 (Pubitemid 39627382)
15. den Daas I, Tepper PG, Rollema H et al (1990) Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model. Naunyn Schmiedebergs Arch Pharmacol 342: 655-699
16. D Devos French DUODOPA Study Group 2009 Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease Mov Disord 24 993 1000 19253412 10.1002/mds.22450
17. K Eggert C Schrader M Hahn, et al. 2008 Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications Clin Neuropharmacol 31 151 166 18520982 10.1097/wnf.0b013e31814b113e 1:CAS:528:DC%2BD1cXmsFylsr4%3D (Pubitemid 351787111)
18. N Giladi B Boroojerdi AD Korczyn, et al. 2007 Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole Mov Disord 22 2398 2404 17935234 10.1002/mds.21741 (Pubitemid 351155987)
19. Giladi N, Jankovic J, Watts RL et al (2010) Effects of Long-Term Treatment With Rotigotine Transdermal Patch on Dyskinesias in Early-stage Parkinson's Disease (PD): results from Two Open-Label Extension Trials. European Federation of Neurological Societies-14th Congress, Eur J Neurol 17(suppl 3):121, abs. P1113
20. IK Goerendt C Messa AD Lawrence 2003 Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study Brain 126 312 325 12538400 10.1093/brain/awg035 (Pubitemid 36172738)
21. JL Goggi A Sardini A Egerton, et al. 2007 Agonist-dependent internalization of D2 receptors: imaging quantification by confocal microscopy Synapse 61 231 241 17230553 10.1002/syn.20360 1:CAS:528:DC%2BD2sXhvFWjt7c%3D
22. Y Goto S Otani AA Grace 2007 The Yin and Yang of dopamine release: a new perspective Neuropharmacology 53 583 587 17709119 10.1016/j.neuropharm.2007.07. 007 1:CAS:528:DC%2BD2sXhtFekurbN (Pubitemid 47516678)
23. AA Grace 1991 Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia Neuroscience 41 1 24 1676137 10.1016/0306-4522(91)90196-U 1:CAS:528: DyaK3MXisVGiur8%3D
24. AA Grace 2008 Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy Mov Disord 23 S3 560 569 10.1002/mds.22020
25. RG Holloway I Shoulson S Fahn Parkinson Study Group, et al. 2004 Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial Arch Neurol 61 1044 1053 15262734 10.1001/archneur.61.7.1044 (Pubitemid 38915945)
26. H Honig A Antonini P Martinez-Martin, et al. 2009 Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life Mov Disord 24 1468 1474 19425079 10.1002/mds.22596
27. D Isacson K Bingefors IS Kristiansen, et al. 2008 Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion Acta Neurol Scand 118 379 386 18547273 10.1111/j.1600-0404. 2008.01049.x 1:STN:280:DC%2BD1cjkvVeqtw%3D%3D
28. MJ Jackson LA Smith G Al-Barghouthy, et al. 2007 Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets Exp Neurol 204 162 170 17113078 10.1016/j.expneurol.2006.10.005 1:CAS:528:DC%2BD2sXisVWnsb0%3D (Pubitemid 46330268)
29. P Jenner 2003 The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease Parkinsonism Relat Disord 9 131 137 12573867 10.1016/S1353-8020(02)00115-3 (Pubitemid 36173561)
30. P Jenner 2008 Preventing and controlling dyskinesia in Parkinson's disease-a view of current knowledge and future opportunities Mov Disord 23 S3 585 598 10.1002/mds.22022
31. P Jenner 2009 From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease Parkinsonism Relat Disord 15 S4 18 10.1016/S1353-8020(09)70829-6
32. Jennings DL, Tabamo R, Seibyl JP et al (2007) InSPECT: investigating the effect of short-term treatment with pramipexole or l-dopa on [123I] β-CIT and SPECT imaging. Mov Disord 22(S16):143-144
33. JL Juncos TM Engber R Raisman, et al. 1989 Continuous and intermittent l-dopa differentially affect basal ganglia function Ann Neurol 25 473 478 2774488 10.1002/ana.410250509 1:CAS:528:DyaL1MXktlemu78%3D (Pubitemid 19136678)
34. F Karoum WJ Freed LW Chuang 1988 d-dopa and l-dopa similarly elevate brain dopamine and produce turning behavior in rats Brain Res 440 190 194 3129126 10.1016/0006-8993(88)91176-6 1:CAS:528:DyaL1cXht1Cns7k%3D (Pubitemid 18058590)
35. R Katzenschlager A Hughes A Evans, et al. 2005 Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges Mov Disord 20 151 157 15390035 10.1002/mds.20276 (Pubitemid 40361117)
36. J Kehr XJ Hu M Goiny DK Scheller 2007 Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation J Neural Transm 114 1027 1031 17431734 10.1007/s00702-007-0719-3 1:CAS:528:DC%2BD2sXotFWrtrw%3D (Pubitemid 47106455)
37. IS Kristiansen K Bingefors D Nyholm, et al. 2009 Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study Appl Health Econ Health Policy 7 167 180 19799471
38. R Kurlan JG Nutt WR Woodward 1988 Duodenal and gastric delivery of l-dopa in parkinsonism Ann Neurol 23 589 595 3408240 10.1002/ana.410230611 1:STN:280:DyaL1czgvVClsw%3D%3D
39. MC Kurth JW Tetrud CM Tanner, et al. 1993 Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations Neurology 43 1698 1703 8414015 1:STN:280:DyaK2c%2FitVaruw%3D%3D (Pubitemid 23307938)
40. T Kvernmo S Hartter E Burger 2006 A review of the receptor-binding and pharmacokinetic properties of dopamine agonists Clin Ther 28 1065 1078 16982285 10.1016/j.clinthera.2006.08.004 1:CAS:528:DC%2BD28XhtVGmsrnO (Pubitemid 44374749)
41. PA LeWitt KE Lyons R Pahwa 2007 Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study Neurology 68 16 1262 1267 17438216 10.1212/01.wnl.0000259516.61938.bb 1:CAS:528:DC%2BD2sXktFOntLg%3D (Pubitemid 46625971)
42. HS Lindgren DR Andersson S Lagerkvist, et al. 2010 l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J Neurochem 112 1465 1476 20050978 10.1111/j.1471-4159.2009.06556.x 1:CAS:528:DC%2BC3cXjsFaku7o%3D
43. PA Loeschmann PN Chong M Nomoto, et al. 1989 Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437 Eur J Pharmacol 166 373 380 10.1016/0014-2999(89)90348-8 (Pubitemid 19195319)
44. Loeschmann PA, Smith LA, Lange KW et al (1992) Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology (Berl) 109:49-56
45. M Malik JO Andreas K Hnatkova, et al. 2008 Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine Clin Pharmacol Ther 84 595 603 18650802 10.1038/clpt.2008.143 1:CAS:528: DC%2BD1cXht1OisLvI
46. AJ Manson H Hanagasi K Turner, et al. 2001 Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations Brain 124 331 340 11157560 10.1093/brain/124.2.331 1:STN:280:DC%2BD3M7ls1Ogtg%3D%3D (Pubitemid 32142405)
47. EC Maratos MJ Jackson RK Pearce, et al. 2001 Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus) Mov Disord 16 631 641 11481686 10.1002/mds.1149 1:STN:280:DC%2BD3Mvjtlyksw%3D%3D (Pubitemid 36040842)
48. EC Maratos MJ Jackson RK Pearce, et al. 2003 Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus) Exp Neurol 179 90 102 12504871 10.1006/exnr.2002.8055 1:CAS:528:DC%2BD38Xps12ku7Y%3D (Pubitemid 36062622)
49. MH Marion F Stocchi NP Quinn, et al. 1986 Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data Clin Neuropharmacol 9 165 181 3708602 10.1097/00002826-198604000-00008 1:STN:280:DyaL283hslyhsA%3D%3D (Pubitemid 16111367)
50. DW Miller ED Abercrombie 1999 Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine- treated rats J Neurochem 72 1516 1522 10098856 10.1046/j.1471-4159.1999.721516.x 1:CAS:528:DyaK1MXitFCksL0%3D (Pubitemid 29140823)
51. M Morissette M Goulet JJ Soghomonian, et al. 1997 Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy Brain Res Mol Brain Res 49 55 62 9387863 10.1016/S0169-328X(97)00123-X 1:CAS:528:DyaK2sXlsleqtLk%3D (Pubitemid 27453114)
52. MM Mouradian IJ Heuser F Baronti, et al. 1990 Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease Ann Neurol 27 18123 10.1002/ana.410270105 (Pubitemid 20031354)
53. MD Muenter GM Tyce 1971 l-dopa therapy of Parkinson's disease: plasma l-dopa concentration, therapeutic response, and side effects Mayo Clin Proc 46 231 239 5573818 1:STN:280:DyaE3M7osVSrsQ%3D%3D
54. D Nilsson LE Hansson K Johansson, et al. 1998 Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease Acta Neurol Scand 97 175 183 9531434 10.1111/j.1600-0404. 1998.tb00633.x 1:CAS:528:DyaK1cXhslGisLo%3D (Pubitemid 28254914)
55. D Nilsson D Nyholm SM Aquilonius 2001 Duodenal levodopa infusion in Parkinson's disease-long-term experience Acta Neurol Scand 104 343 348 11903087 10.1034/j.1600-0404.2001.00153.x 1:CAS:528:DC%2BD38XhsVehsA%3D%3D (Pubitemid 33107378)
56. JG Nutt JH Carter ES Lea, et al. 1997 Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease Mov Disord 12 285 292 9159720 10.1002/mds.870120304 1:STN:280:DyaK2szgtleqtw%3D%3D (Pubitemid 27216124)
57. JG Nutt JA Obeso F Stocchi 2000 Continuous dopamine-receptor stimulation in advanced Parkinson's disease Trends Neurosci 23 10 S 109 115 10.1016/S1471-1931(00)00029-X
58. D Nyholm H Askmark C Gomes-Trolin, et al. 2003 Optimizing pharmacokinetics: intestinal infusion versus oral sustained-release tablets Clin Neuropharmacol 26 156 163 12782919 10.1097/00002826-200305000-00010 1:CAS:528:DC%2BD3sXktlyrsLw%3D (Pubitemid 36676295)
59. D Nyholm AI Nilsson Remahl N Dizdar 2005 Duodenal l-dopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease Neurology 64 216 223 15668416 10.1212/01.WNL.0000149637.70961.4C 1:STN:280: DC%2BD2M%2FktFSnsQ%3D%3D
60. D Nyholm T Lewander A Johansson, et al. 2008 Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure Clin Neuropharmacol 2008 31 63 73 10.1097/WNF.0b013e3180ed449f (Pubitemid 351489331)
61. WH Oertel E Wolters C Sampaio, et al. 2006 Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study Mov Disord 21 343 353 16211594 10.1002/mds.20724
62. CW Olanow MB Stern K Sethi 2009 The scientific and clinical basis for the treatment of Parkinson disease Neurology 72 1 136 10.1212/WNL.0b013e3181a1d44c
63. Papathanou M, Kooyman E, van der Laan R et al (2009) A preliminary pharmacokinetic study comparing l-DOPA and duodopa in adult rats. Poster 2.193, World Federation of Neurology XIX Congress, Miami Beach, Florida
64. Papathanou M, van der Laan R, Jenner P et al (2011) Both pulsatile and continuous administration of l-dopa prime for abnormal involuntary movements in 6-OHDA-lesioned rats [in revision]
65. Parkinson Study Group 2003 A controlled trial of rotigotine monotherapy in early Parkinson's disease Arch Neurol 60 1721 1728 10.1001/archneur.60.12. 1721 (Pubitemid 37521625)
66. RK Pearce T Banerji Jenner P, et al. 1998 De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset Mov Disord 13 234 241 9539335 10.1002/mds.870130207 1:STN:280:DyaK1c7pvVOnsw%3D%3D (Pubitemid 28127797)
67. B Picconi D Centonze K Hakansson, et al. 2003 Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia Nat Neurosci 6 501 506 12665799 1:CAS:528:DC%2BD3sXjtFKnsLo%3D (Pubitemid 36514698)
68. WH Poewe O Rascol N Quinn, et al. 2007 Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial Lancet Neurol 6 6 513 520 17509486 10.1016/S1474-4422(07)70108-4 1:CAS:528:DC%2BD2sXmslKktr8%3D (Pubitemid 46734759)
69. N Quinn 2001 A multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of rotigotine constant delivery system (CDS) in patients with advanced Parkinson's disease Parkinsonism Rel Disord 7 S1 S66
70. N Quinn JD Parkes CD Marsden 1984 Control of on/off phenomenon by continuous intravenous infusion of levodopa Neurology 34 1131 1136 6540399 1:STN:280:DyaL2c3ntFWqtA%3D%3D (Pubitemid 14068582)
71. SS Rao LA Hofmann A Shakil 2006 Parkinson's disease: diagnosis and treatment Am Fam Phys 74 12 2046 2054
72. O Rascol DJ Brooks AD Korczyn, et al. 2000 A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 1484 1491 10816186 10.1056/NEJM200005183422004 1:CAS:528:DC%2BD3cXjvVeitrc%3D (Pubitemid 30318272)
73. O Rascol DJ Brooks AD Korczyn, et al. 2006 Development of dyskinesias in a 5-year trial of ropinirole and l-dopa Mov Disord 21 1844 1850 16958094 10.1002/mds.20988 (Pubitemid 44848929)
74. UK Rinne F Bracco C Chouza, et al. 1998 Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group Drugs 55 S1 23 30 9483167 10.2165/00003495-199855001-00004 1:CAS:528:DyaK1cXhtVGjsr4%3D (Pubitemid 28051035)
75. DB Rye 2004 The two faces of Eve: dopamine's modulation of wakefulness and sleep Neurology 63 8,S3 2 7
76. JI Sage S Trooskin PK Sonsalla, et al. 1988 Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism Ann Neurol 24 87 89 3415201 10.1002/ana.410240116 1:STN:280:DyaL1czisFejsA%3D%3D
77. AH Schapira CW Olanow 2004 Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 291 358 364 14734599 10.1001/jama.291.3.358 1:CAS:528:DC%2BD2cXmtlelsg%3D%3D (Pubitemid 38101609)
78. D Scheller C Ullmer R Berkels, et al. 2009 The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease Naunyn Schmiedebergs Arch Pharmacol 379 73 86 18704368 10.1007/s00210-008-0341-4 1:CAS:528:DC%2BD1MXhtlOjsbk%3D
79. WJ Schmidt H Lebsanft M Heindl, et al. 2008 Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements J Neural Transm 115 1385 1392 18726139 10.1007/s00702-008-0102-z 1:CAS:528:DC%2BD1cXhtFensbfP
80. LA Schuh JP Bennett Jr 1993 Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease Neurology 43 1545 1550 8351009 1:STN:280: DyaK3szlsVGlug%3D%3D (Pubitemid 23230540)
81. W Schultz 1994 Behavior-related activity of primate dopamine neurons Rev Neurol (Paris) 150 634 639 1:STN:280:DyaK2M3ntlyrug%3D%3D (Pubitemid 24332154)
82. W Shen M Flajolet P Greengard, et al. 2008 Dichotomous dopaminergic control of striatal synaptic plasticity Science 321 848 851 18687967 10.1126/science.1160575 1:CAS:528:DC%2BD1cXptlyhsLw%3D
83. Stocchi F (2008) Use of apomorphine in Parkinson's disease. Neurol Sci 29:S383-386
84. F Stocchi S Ruggieri L Vacca, et al. 2002 Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease Brain 125 2058 2066 12183351 10.1093/brain/awf214
85. F Stocchi L Vacca S Ruggieri, et al. 2005 Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study Arch Neurol 62 905 910 15956161 10.1001/archneur.62.6. 905 (Pubitemid 40973452)
86. F Stocchi O Rascol K Kieburtz, et al. 2010 Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study Ann Neurol 68 18 27 20582993 10.1002/ana.22060 1:CAS:528: DC%2BC3cXpslagsrk%3D
87. KA Stockwell D Scheller S Rose, et al. 2009 Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction Exp Neurol 219 533 542 19619533 10.1016/j.expneurol.2009.07.011 1:CAS:528:DC%2BD1MXhtFajs7vM
88. KA Stockwell DK Scheller LA Smith, et al. 2010 Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets Exp Neurol 221 79 85 19833125 10.1016/j.expneurol.2009.10.004 1:CAS:528:DC%2BC3cXotFWl
89. J Van der Weide JB De Vries PG Tepper, et al. 1986 Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734 Eur J Pharmacol 125 273 282 3743637 10.1016/0014-2999(86) 90037-3 (Pubitemid 16075440)
90. J Van der Weide ME Tendijck PG Tepper, et al. 1988 The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors Eur J Pharmacol 146 319 326 2836210 10.1016/0014-2999(88) 90309-3 (Pubitemid 18068508)
91. BJ Venton H Zhang PA Garris, et al. 2003 Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing J Neurochem 87 1284 1295 14622108 10.1046/j.1471-4159.2003.02109.x 1:CAS:528:DC%2BD3sXps1OhsLc%3D (Pubitemid 37485084)
92. RL Watts J Jankovic C Waters, et al. 2007 Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease Neurology 68 272 276 17202432 10.1212/01.wnl.0000252355.79284.22 1:CAS:528:DC%2BD2sXlt12msg%3D%3D (Pubitemid 46148338)
93. RL Watts R Pahwa KE Lyons, et al. 2009 Long-term safety of rotigotine transdermal patch in early-stage Parkinson's disease: results from 4 years Mov Disord 24 S1 286